Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 18/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20607269 | 0.92 | PDE3A (0.46) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607025 | 0.90 | PDE3A (0.46) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607024 | 0.90 | PDE3A (0.44) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607393 | 0.90 | PDE3A (0.47) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607372 | 0.89 | PDE3A (0.43) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607079 | 0.89 | PDE3A (0.43) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL23456406 | 0.89 | PDE3A (0.43) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607134 | 0.86 | PDE3A (0.47) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607097 | 0.85 | PDE3A (0.44) | PDE3APDE4BPDE3BPDE4APDE4C | |
| SCHEMBL20607332 | 0.84 | PDE3A (0.44) | PDE3APDE4BPDE3BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-3423440-B9 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3423440-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3A 2826/4885PDE4B 2646/4885PDE3B 2704/4885 |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3A 2826/4885PDE4B 2646/4885PDE3B 2704/4885 |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3A 2826/4885PDE4B 2646/4885PDE3B 2704/4885 |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | PDE3A 2826/4885PDE4B 2646/4885PDE3B 2704/4885 |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | VHL, H1-5, PRMT5 | PDE3A 2826/4885PDE4B 2646/4885PDE3B 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.